Overview

Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 CEUS for characterization of solid pancreatic lesions in subjects with suspected PDAC using transabdominal US.
Phase:
Phase 2
Details
Lead Sponsor:
Bracco Diagnostics, Inc
Collaborator:
National Institutes of Health (NIH)